替吉奥+奥沙利铂联合曲妥珠单抗对HER2阳性进展期胃癌患者的影响  

Analysis of the effect of Trastuzumab combined with SOX therapy in the treatment of HER2 positive advanced gastric cancer

作　　者：宋志刚[1] 张旭[2] 汪济东[1] 孙琦[1] 许杨[1] 李星缘 

机构地区：[1]中国人民解放军海军安庆医院肿瘤科,安徽安庆246003 [2]六安市中医院脾胃病科,安徽六安237000

出　　处：《中国中西医结合消化杂志》2017年第10期730-733,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]探讨曲妥珠单抗联合替吉奥以及奥沙利铂在人类表皮生长因子受体2(HER2)阳性进展期胃癌患者中的临床价值。[方法]连续性纳入2014年4月~2016年4月我院所收治的晚期胃癌患者60例,并随机分为研究组和对照组。对照组给予替吉奥及奥沙利铂(SOX方案)治疗,研究组给予曲妥珠单抗联合SOX方案治疗。3个疗程后比较2组临床治疗效果、血清肿瘤标志物及新生血管标志物浓度差异等。[结果]研究组疾病控制率显著性高于对照组,差异有统计学意义(χ~2=5.934,P=0.015)。治疗后研究组血清肿瘤标志物糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、糖类抗原(CA125)、甲胎蛋白(AFP)以及组织多肽特异性抗原(TPS)浓度均显著性低于对照组,差异有统计学意义(P<0.05);研究组血清新生血管标志物血管内皮生长因子(VEGF)、内皮抑素(ES)、血管生成素-2(Ang-2)、色素上皮衍生因子(PEDF)浓度均显著性低于对照组,差异有统计学意义(P<0.05)。[结论]曲妥珠单抗联合SOX方案治疗HER2阳性进展期胃癌临床疗效优于单纯SOX方案,值得临床推广。[Objective]To investigate the clinical value of Trastuzumab combined with SOX therapy in the treatment of HER2 positive advanced gastric cancer.[Methods]60cases with advanced gastric cancer were continuously enrolled from Apr.2014 to Apr.2016,and were randomly divided into study group and control group.The control group was treated with SOX therapy,while the study group was treated with Trastuzumab combined with SOX therapy.Clinical outcomes,serum tumor markers and neonatal blood vessel markers were compared between two groups after three courses.[Results]The disease control rate in study group was significantly higher than that in the control group（χ~2=5.934,P=0.015）.After treatment,serum tumor markers carbohydrate antigen 19-9（CA19-9）,carcinoembryonic antigen（CEA）and carbohydrate antigen 125（CA125）,alpha fetoprotein（AFP）and tissue polypeptide specific antigen（TPS）concentrations in the study group were significantly lower than those in the control group（P0.05）;and serum angiogenesis markers,serum vascular endothelial growth factor（VEGF）,endostatin（ES）,angiogenin-2（Ang-2）,pigment epithelium derived factor（PEDF）concentrations in the study group were also significantly lower than those in the control group,the differences were statistically significant（P0.05）.[Conclu-sion]Trastuzumab combined with SOX therapy is better than simple SOX therapy in the treatment of HER2 positive advanced gastric cancer and deserves clinical expansion

关 键 词：曲妥珠单抗 替吉奥 奥沙利铂 进展期胃癌 HER2阳性 

分 类 号：R735.2[医药卫生—肿瘤]